Search
Johnson & Johnson
JNJAdd to Watchlist
240.871USD
+1.792+0.75%
Market hours （ET）Quotes delayed by 15 min
579.68BMarket Cap
27.57P/E TTM
TradingKey Stock Score of Johnson & Johnson
Currency: USD Updated: 2026-06-23Key Insights
Johnson & Johnson's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 253.77.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Johnson & Johnson's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
49°C
Very Low
Very High
Neutral
Johnson & Johnson Highlights
StrengthsRisks
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 94.19B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.
Overvalued
The company’s latest PE is 27.36, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.78B shares, decreasing 3.55% quarter-over-quarter.
Held by Donald Yacktman
Star Investor Donald Yacktman holds 1.31M shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
253.769
Target Price
+9.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Peer Comparison
Pharmaceuticals
Johnson & Johnson
JNJ
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tarsus Pharmaceuticals Inc
TARS
9.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Vertex Pharmaceuticals Inc
VRTX
9.15 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.85 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Johnson & Johnson?
The TradingKey Stock Score provides a comprehensive assessment of Johnson & Johnson based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Johnson & Johnson’s performance and outlook.
How do we generate the financial health score of Johnson & Johnson?
To generate the financial health score of Johnson & Johnson, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Johnson & Johnson's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Johnson & Johnson.
How do we generate the company valuation score of Johnson & Johnson?
To generate the company valuation score of Johnson & Johnson, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Johnson & Johnson’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Johnson & Johnson’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Johnson & Johnson.
How do we generate the earnings forecast score of Johnson & Johnson?
To calculate the earnings forecast score of Johnson & Johnson, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Johnson & Johnson’s future.
How do we generate the price momentum score of Johnson & Johnson?
When generating the price momentum score for Johnson & Johnson, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Johnson & Johnson’s prices. A higher score indicates a more stable short-term price trend for Johnson & Johnson.
How do we generate the institutional confidence score of Johnson & Johnson?
To generate the institutional confidence score of Johnson & Johnson, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Johnson & Johnson’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Johnson & Johnson.
How do we generate the risk management score of Johnson & Johnson?
To assess the risk management score of Johnson & Johnson, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Johnson & Johnson’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Johnson & Johnson.
